Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

3.4.22.B70: SENP1 peptidase

This is an abbreviated version!
For detailed information about SENP1 peptidase, go to the full flat file.

Word Map on EC 3.4.22.B70

Reaction

The enzyme catalyzes two essential functions in the SUMO pathway: processing of full-length SUMO-1, SUMO-2 and SUMO-3 to their mature forms and deconjugation of SUMO-1, SUMO-2 and SUMO-3 from targeted proteins. Deconjugates SUMO-1 from homeodomain-interacting protein kinase 2. Deconjugates SUMO-1 from histone deacetylase 1, which decreases its transcriptional repression activity. Cleavage of Gly97-/-His98 bond in the SUMO-1 precursor with release of the propeptide His-Ser-Thr-Val. Cleavage of Gly93-/-Val94 bond in the SUMO-2 precursor with release of the propeptide Val94-Thyr. Cleavage of the Gly92-/-Val93 in the SUMO-3 precursor with release of the propeptide Pro-Glu-Ser-Ser-Leu-Ala-Gly-His-Ser-Phe. =

Synonyms

C13orf22l, SENP, SENP1, sentrin-specific protease 1, sentrin/SUMO-specific protease 1, small ubiquitin-like modifier protein-specific protease 1, small ubiquitin-related modifier-specific isopeptidase, SUMO isopeptidase, SUMO protease, SUMO protein-specific protease 1, SUMO-specific isopeptidase, SUMO-specific protease, SUMO-specific protease 1, ubiquitin-specific protease-like 1, USPL1

ECTree

     3 Hydrolases
         3.4 Acting on peptide bonds (peptidases)
             3.4.22 Cysteine endopeptidases
                3.4.22.B70 SENP1 peptidase

Disease

topprint

Disease on EC 3.4.22.B70 - SENP1 peptidase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Astrocytoma
Inhibition of SUMO-specific protease 1 induces apoptosis of astroglioma cells by regulating NF-?B/Akt pathways.
Breast Neoplasms
Exploring the association between genetic variation in the SUMO isopeptidase gene USPL1 and breast cancer through integration of data from the population-based GENICA study and external genetic databases.
Burkitt Lymphoma
Down-regulation of SENP1 Expression Increases Apoptosis of Burkitt Lymphoma Cells.
Carcinogenesis
Melatonin downregulates nuclear receptor RZR/ROR? expression causing growth-inhibitory and anti-angiogenesis activity in human gastric cancer cells in vitro and in vivo.
Cardiomyopathies
SENP5, a SUMO isopeptidase, induces apoptosis and cardiomyopathy.
Colonic Neoplasms
SUMO-specific protease 1 regulates the in vitro and in vivo growth of colon cancer cells with the upregulated expression of CDK inhibitors.
Colorectal Neoplasms
MiR-133a-3p Targets SUMO-Specific Protease 1 to Inhibit Cell Proliferation and Cell Cycle Progress in Colorectal Cancer.
Heart Failure
Astragaloside IV alleviates heart failure by regulating SUMO-specific protease 1.
Keloid
Sumoylation enhances the activity of the TGF-?/SMAD and HIF-1 signaling pathways in keloids.
Leukemia
Deficiency of SUMO-specific protease 1 induces arsenic trioxide-mediated apoptosis by regulating XBP1 activity in human acute promyelocytic leukemia.
Leukemia, Promyelocytic, Acute
Deficiency of SUMO-specific protease 1 induces arsenic trioxide-mediated apoptosis by regulating XBP1 activity in human acute promyelocytic leukemia.
Lung Neoplasms
Up-regulation of microRNA-138 induce radiosensitization in lung cancer cells.
Neoplasm Metastasis
SUMO-specific protease 1 promotes prostate cancer progression and metastasis.
Neoplasms
Exploring the association between genetic variation in the SUMO isopeptidase gene USPL1 and breast cancer through integration of data from the population-based GENICA study and external genetic databases.
Inhibition of SUMO-specific protease 1 induces apoptosis of astroglioma cells by regulating NF-?B/Akt pathways.
SENP1 promotes proliferation of clear cell renal cell carcinoma through activation of glycolysis.
Vialinin A and thelephantin G, potent inhibitors of tumor necrosis factor-? production, inhibit sentrin/SUMO-specific protease 1 enzymatic activity.
[SUMO-specific protease 1 and cancer]
Osteosarcoma
Plasma Exosome-Derived Sentrin SUMO-Specific Protease 1: A Prognostic Biomarker in Patients With Osteosarcoma.
Pancreatic Neoplasms
A cellular and bioinformatics analysis of the SENP1 SUMO isopeptidase in pancreatic cancer.
SUMO-specific protease 1 regulates pancreatic cancer cell proliferation and invasion by targeting MMP-9.
Prostatic Neoplasms
2-(4-Chlorophenyl)-2-oxoethyl 4-benzamidobenzoate derivatives, a novel class of SENP1 inhibitors: Virtual screening, synthesis and biological evaluation.
Induction of the SUMO-specific protease 1 transcription by the androgen receptor in prostate cancer cells.
Momordin Ic, a new natural SENP1 inhibitor, inhibits prostate cancer cell proliferation.
Prognostic impact of SUMO-specific protease 1 (SENP1) in prostate cancer patients undergoing radical prostatectomy.
Small ubiquitin-like modifier protein-specific protease 1 and prostate cancer.
SUMO-specific protease 1 (SENP1) reverses the hormone-augmented SUMOylation of androgen receptor and modulates gene responses in prostate cancer cells.
SUMO-specific protease 1 promotes prostate cancer progression and metastasis.
Triptolide inhibits the proliferation of prostate cancer cells and down-regulates SUMO-specific protease 1 expression.
Stomach Neoplasms
Melatonin downregulates nuclear receptor RZR/ROR? expression causing growth-inhibitory and anti-angiogenesis activity in human gastric cancer cells in vitro and in vivo.